Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound

ABSTRACT

An organometallic compound represented by Formula 1:2wherein, in Formula 1, groups and variables are the same as described in the specification.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to Korean Patent Applications No. 10-2017-0127764, filed on Sep. 29, 2017, and 10-2018-0113886, filed on Sep. 21, 2018, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. § 119, the contents of which are incorporated herein in their entirety by reference.

BACKGROUND 1. Field

One or more embodiments relate to an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

2. Description of the Related Art

Organic light-emitting devices (OLEDs) are self-emission devices, which have superior characteristics in terms of a viewing angle, a response time, a brightness, a driving voltage, and a response speed, and which produce full-color images.

In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transit from an excited state to a ground state, thereby generating light.

Meanwhile, luminescent compounds may be used to monitor, sense, or detect a variety of biological materials including cells and proteins. An example of the luminescent compounds includes a phosphorescent luminescent compound.

Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.

SUMMARY

Aspects of the present disclosure provide an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

An aspect of the present disclosure provides an organometallic compound represented by Formula 1:

In Formula 1,

M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au),

X₁ may be N,

X₂ to X₄ may each independently be N or C,

a bond between X₁ and M may be a covalent bond,

two bonds selected from a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may each be a coordinate bond and the remaining bond may be a covalent bond,

ring CY₁₁ and ring CY₁₂ may each independently be a C₅-C₁₅ carbocyclic group or a C₁-C₁₅ heterocyclic group,

ring CY₂ to ring CY₄ may each independently be a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group,

T₁ and T₂ may each independently be selected from a single bond, a double bond, *—N(R₅)—*′, *—B(R₅)—*′, *—P(R₅)—*′, *—C(R₅)(R₆)—*′, *—Si(R₅)(R₆)—*′, *—Ge(R₅)(R₆)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₅)═*′, *═C(R₅)—*′, *—C(R₅)═C(R₆)—*′, *—C(R_(5a))(R_(5b))—C(R_(6a))(R_(6b))—*′, *—C(═S)—*′, and *—C≡C—*′, and * and *′ each indicate a binding site to a neighboring atom,

X₁₅ may be a single bond, O, S, Se, N(R₁₅), C(R₁₅)(R₁₆), or Si(R₁₅)(R₁₆),

R₅ and R₆, and R₁₅ and R₁₆ may optionally be linked via a single bond, a double bond, or a first linking group to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀ alkyl group, a substituted or unsubstituted C₂-C₆₀ alkenyl group, a substituted or unsubstituted C₂-C₆₀ alkynyl group, a substituted or unsubstituted C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉),

a1 to a4 may each independently be an integer from 0 to 20,

two or more groups selected from a plurality of neighboring groups R₁ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

two or more groups selected from a plurality of neighboring groups R₂ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

two or more groups selected from a plurality of neighboring groups R₃ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

two or more groups selected from a plurality of neighboring groups R₄ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

two or more groups selected from R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a),

R_(1a) may be defined the same as above R₁,

at least one substituent of the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(═O)(Q₁₈)(Q₁₉);

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(═O)(Q₂₈)(Q₂₉); and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(═O)(Q₃₈)(Q₃₉),

Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₁-C₆₀ alkyl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

Another aspect of the present disclosure provides an organic light-emitting device including:

a first electrode;

a second electrode; and

an organic layer disposed between the first electrode and the second electrode,

wherein the organic layer includes an emission layer, and

wherein the organic layer includes at least one organometallic compound.

The organometallic compound may act as a dopant in the organic layer.

Another aspect of the present disclosure provides a diagnostic composition including at least one of the organometallic compound represented by Formula 1.

BRIEF DESCRIPTION OF THE DRAWING

These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with FIGURE which is a schematic view of an organic light-emitting device according to an embodiment.

DETAILED DESCRIPTION

Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the FIGURES, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the FIGURES, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.

Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

“About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within ±30%, 20%, 10%, 5% of the stated value.

An aspect of the present disclosure provides an organometallic compound represented by Formula 1:

In Formula 1, M may be beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au).

For example, M may be Pd, Pt, or Au, but embodiments of the present disclosure are not limited thereto.

In Formula 1, X₁ may be N, and X₂ to X₄ may each independently be N or C.

In an embodiment, in Formula 1, a bond between X₁ and M may be a covalent bond, and two bonds selected from a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M may each be a coordinate bond and the remaining bond may be a covalent bond. In this regard, the organometallic compound represented by Formula 1 may be electrically neutral.

For example, in Formula 1,

i) X₂ and X₃ may each be N, and X₄ may be C,

ii) X₂ and X₄ may each be N, and X₃ may be C,

iii) a bond between X₂ and M and a bond between X₃ and M may each be a coordinate bond, and a bond between X₄ and M may be a covalent bond, or

iv) a bond between X₂ and M and a bond between X₄ and M may each be a coordinate bond, and a bond between X₃ and M may be a covalent bond, but embodiments of the present disclosure are not limited thereto.

In Formula 1, ring CY₁₁ and ring CY₁₂ may each independently be a C₅-C₁₅carbocyclic group or a C₁-C₁₅ heterocyclic group, ring CY₂ to ring CY₄ may each independently be a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group.

In an embodiment, ring CY₁₁, ring CY₁₂, and ring CY₂ to ring CY₄ may each independently be selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a thiophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, a 5,6,7,8-tetrahydroquinoline group, an indazole group, a benzofluorene group, a benzocarbazole group, a naphthobenzofuran group, a naphthobenzothiophene group, and a naphtobenzosilole group, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, ring CY₁₁, ring CY₁₂, and ring CY₂ to ring CY₄ may each independently be selected from i) a first ring, ii) a second ring, iii) a condensed ring in which at least two first rings are condensed, iv) a condensed ring in which at least two second rings are condensed, and v) a condensed ring in which at least one first ring and at least one second ring are condensed,

the first ring may be selected from a cyclopentadiene group, a furan group, a thiophene group, a pyrrole group, a silole group, an oxazole group, an isoxazole group, an oxadiazole group, an isozadiazole group, an oxatriazole group, an isoxatriazole group, a thiazole group, an isothiazole group, a thiadiazole group, an isothiadiazole group, a thiatriazole group, an isothiatriazole group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an azasilole group, a diazasilole group, and a triazasilole group, and

the second ring may be selected from an adamantane group, a norbornane group, a norbornene group, a cyclohexane group, a cyclohexene group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, and a triazine group.

In Formula 1, T₁ and T₂ may each independently be selected from a single bond, a double bond, *—N(R₅)—*′, *—B(R₅)—*′, *—P(R₅)—*′, *—C(R₅)(R₆)—*′, *—Si(R₅)(R₆)—*′, *—Ge(R₅)(R₆)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₅)═*′ *═C(R₅)—*′, *—C(R₅)═C(R₆)—*′, *—C(R_(5a))(R_(5b))—C(R_(6a))(R_(6b))—*′, *—C(═S)—*′, and *—C≡C—*′, wherein * and *′ each independently indicate a binding site to a neighboring atom. R₅ and R₆ may each independently be defined the same as described above, R₅ and R₆ may optionally be linked each other via a single bond, a double bond, or a first linking group to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a) and R_(1a) may be defined the same as above R₁.

The first linking group may be selected from *—N(R₉)—*′, *—B(R₉)—*′, *—P(R₉)—*′, *—C(R₉)(R₁₀)—*′, *—Si(R₉)(R₁₀)—*′, *—Ge(R₉)(R₁₀)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₉)═*′, *═C(R₉)—*′, *—C(R₉)═C(R₁₀)—*′, *—C(═S)—*′, and *—C≡C—*′, wherein R₉ and R₁₀ may each independently be defined the same as above R₅, and * and *′ each independently indicate a binding site to a neighboring atom.

In an embodiment, i) T₁ and T₂ may each independently be a single bond, or ii) T₁ may be a single bond and T₂ may be *—N(R₅)—*′, *—B(R₅)—*′, *—P(R₅)—*′, *—C(R₅)(R₆)—*′, *—Si(R₅)(R₆)—*′, *—S—*′, *—Se—*′ or *—O—*′.

In Formula 1, X₁₅ may be a single bond, O, S, Se, N(R₁₅), C(R₁₅)(R₁₆), or Si(R₁₅)(R₁₆). R₁₅ and R₁₆ may each independently be the same as described above, and R₁₅ and R₁₆ may optionally be linked each other via a single bond, a double bond, or the first linking group to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a) and R_(1a) may be defined the same as above R₁.

In an embodiment, X₁₅ may be a single bond.

R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀ alkyl group, a substituted or unsubstituted C₂-C₆₀ alkenyl group, a substituted or unsubstituted C₂-C₆₀ alkynyl group, a substituted or unsubstituted C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉). Q₁ to Q₉ may each independently be the same as described above.

For example, R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ may each independently be selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF₅, a C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group;

a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, a phenoxy group, and a naphthoxy group;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, a phenoxy group and a naphthoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and —Si(Q₃₃)(Q₃₄)(Q₃₅); and

—N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉), and

Q₁ to Q₉ and Q₃₃ to Q₃₅ may each independently be selected from:

—CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂;

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and

an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.

In an embodiment, R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ may each independently be selected from hydrogen, deuterium, —F, a cyano group, a nitro group, —SF₅, —CH₃, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a C₁-C₁₀ alkoxy group, groups represented by Formulae 9-1 to 9-19, groups represented by Formulae 10-1 to 10-194, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉) (wherein Q₁ to Q₉ may each independently be the same as described above), but embodiments of the present disclosure are not limited thereto:

In Formulae 9-1 to 9-19 and 10-1 to 10-194, Ph indicates a phenyl group, TMS indicates a trimethylsilyl group, and * indicates a binding site to a neighboring atom.

In an embodiment, at least one of R₁ to R₄ in Formula 1 may not be hydrogen.

In Formula 1, a1 to a4 respectively indicate the number of groups R₁ to R₄, and may each independently be an integer from 0 to 20 (for example, an integer from 0 to 5). When a1 is two or more, two or more groups R₁ may be identical to or different from each other, when a2 is two or more, two or more groups R₂ may be identical to or different from each other, when a3 is two or more, two or more groups R₃ may be identical to or different from each other, and when a4 is two or more, two or more groups R₄ may be identical to or different from each other.

In one or more embodiments, in Formula 1,

ring CY₂ may be a group represented by Formula A2-1′ or A2-2′,

ring CY₃ may be a group represented by Formula A3-1′, A3-2′, or A3-3′,

ring CY₄ may be a group represented by Formula A4-1′ or A4-3′, and

the organometallic compound may satisfy at least one Condition 1 to Condition 3:

Condition 1

ring CY₂ is a group represented by Formula A2-2′;

Condition 2

ring CY₃ is a group represented by Formula A3-2′ or A3-3′; and

Condition 3

ring CY₄ is a group represented by Formula A4-3′.

In Formulae A2-1′, A2-2′, A3-1′, A3-2′, A3-3′, A4-1′, and A4-3′, X₂ to X₄ and ring CY₂ to ring CY₄ may each independently be the same as described herein, Y₃ to Y₈ may each independently be N, B, P, C, or Si,

in Formulae A2-1′ and A2-2′, i) a bond between X₂ and Y₃, a bond between X₂ and Y₄ and a bond between Y₃ and Y₄ may each independently be a single bond or a double bond; or ii) Y₃, X₂, and Y₄ may form a carbene group, *′ indicates a binding site to ring CY₁₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to T₁ in Formula 1, and

in Formula A3-1′, A3-2′, and A3-3′, i) a bond between X₃ and Y₅, a bond between X₃ and Y₆ and a bond between Y₅ and Y₆ may each independently be a single bond or a double bond; or ii) Y₅, X₃, and Y₆ may form a carbene group, *″ indicates a binding site to T₁ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to T₂ in Formula 1,

in Formula A4-1′ and A4-3′, i) a bond between X₄ and Y₇, a bond between X₄ and Y₈ and a bond between Y₇ and Y₈ may each independently be a single bond or a double bond; or ii) Y₇, X₄, and Y₈ may form a carbene group, *′ indicates a binding site to T₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY₁₁ in Formula 1.

In one or more embodiments, in Formula 1,

i) ring CY₂ may be a group represented by Formula A2-2′, and T₁ may be a single bond;

ii) ring CY₃ may be a group represented by Formula A3-2′, and T₂ may be a single bond;

iii) ring CY₃ may be a group represented by Formula A3-3′, and T₁ may be a single bond; or

iv) ring CY₄ may be a group represented by Formula A4-3′, and T₂ may be a single bond, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, in Formula 1,

ring CY₂ may be a group represented by Formula A2-1′,

ring CY₃ may be a group represented by Formula A3-1′,

ring CY₄ may be a group represented by Formula A4-3′, and

T₂ may be a single bond, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments,

i) ring CY₂ may be a group represented by Formula A2-1′, T₁ may be a single bond, ring CY₃ may be a group represented by Formula A3-1′, T₂ may not be a single bond, and ring CY₄ may be a group represented by Formula A4-1′; or

ii) ring CY₂ may be a group represented by Formula A2-1′, T₁ may be a single bond, ring CY₃ may be a group represented by Formula A3-1′, T₂ may be a single bond, and ring CY₄ may be a group represented by Formula A4-3′, but embodiments of the present disclosure are not limited thereto.

In one or more embodiments,

the group represented by Formula A2-2′ may be a group represented by Formula A2-2,

the group represented by Formula A3-2′ may be a group represented by Formula A3-2,

the group represented by represented by Formula A3-3′ may be a group represented by Formula A3-3, and

the group represented by Formula A4-3′ may be a group represented by Formula A4-3, but embodiments of the present disclosure are not limited thereto:

In Formula A2-2, ring CY₂₁ and ring CY₂₂ may each independently be defined as ring CY₁₁, X₂₅ may be a single bond, O, S, Se, N(R₂₅), C(R₂₅)(R₂₆), or Si(R₂₅)(R₂₆), X₂₇ may be N, B, P, C(R₂₇), or Si(R₂₇), X₂, *′, *, and *″ may each independently be defined as X₂, *′, *, and *″ in Formula A2-2′, and R₂₅ to R₂₇ may each independently be defined as R₂,

in Formulae A3-2 and A3-3, ring CY₃₁ and ring CY₃₂ may each independently be defined as ring CY₁₁, X₃₅ may be a single bond, O, S, Se, N(R₃₅), C(R₃₅)(R₃₆), or Si(R₃₅)(R₃₆), X₃₇ may be N, B, P, C(R₃₇), or Si(R₃₇), X₃, *″, * and *′ may each independently be defined as X₃, *″, *, and *′ in Formula A3-2′, and R₃₅ to R₃₇ may each independently be defined as R₃, and

in Formula A4-3, ring CY₄₁ and ring CY₄₂ may each independently be defined as ring CY₁₁, X₄₅ may be a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆), X₄₇ may be N, B, P, C(R₄₇), or Si(R₄₇), X₄, *′, *, and *″ may each independently be defined as X₄, *′, *, and *″ in Formula A4-3′, and R₄₅ to R₄₇ may each independently be defined as R₄.

For example, a moiety represented by

in Formula 1 may be selected from groups represented by Formulae A1-1(1) to A1-1(11):

In Formulae A1-1(1) to A1-1(11),

X₁, X₁₅, and R₁ may each independently be the same as described herein,

R_(1a) and R_(1b) may each independently be defined as R₁,

a18 may be an integer from 0 to 8,

a16 may be an integer from 0 to 6,

a15 may be an integer from 0 to 5,

a14 may be an integer from 0 to 4,

*″ indicates a binding site to ring CY₄ in Formula 1,

* indicates a binding site to M in Formula 1, and

*′ indicates a binding site to ring CY₂ in Formula 1.

In an embodiment, a moiety represented by

in Formula 1 may be selected from groups represented by Formulae A2-1(1) to A2-1(21) and A2-2(1) to A2-2(58):

In Formulae A2-1(1) to A2-1(21) and A2-2(1) to A2-2(58),

X₂ and R₂ may each independently be the same as described herein,

X₂₁ may be O, S, Se, N(R₂₁), C(R₂₁)(R₂₂), or Si(R₂₁)(R₂₂),

X₂₃ may be N or C(R₂₃),

X₂₄ may be N or C(R₂₄),

X₂₅ may be a single bond, O, S, Se, N(R₂₅), C(R₂₅)(R₂₆), or Si(R₂₅)(R₂₆) (for example, a single bond),

X₂₇ may be N, B, P, C(R₂₇), or Si(R₂₇),

R₂₁ to R₂₈ may each independently be defined as R₂,

a26 may be integer from 0 to 6,

a25 may be integer from 0 to 5,

a24 may be integer from 0 to 4,

a23 may be integer from 0 to 3,

a22 may be integer from 0 to 2,

*′ indicates a binding site to ring CY₁₂ in Formula 1,

* indicates a binding site to M in Formula 1, and

*″ indicates a binding site to T₁ in Formula 1.

In an embodiment, a moiety represented by

in Formula 1 may be selected from groups represented by Formulae A3-1(1) to A3-1(21), A3-2(1) to A3-2(58), and A3-3(1) to A3-3(58):

In Formulae A3-1 (1) to A3-1 (21), A3-2(1) to A3-2(58), and A3-3(1) to A3-3(58),

X₃ and R₃ may each independently be the same as described herein,

X₃₁ may be O, S, Se, N(R₃₁), C(R₃₁)(R₃₂), or Si(R₃₁)(R₃₂),

X₃₃ may be N or C(R₃₃),

X₃₄ may be N or C(R₃₄),

X₃₅ may be a single bond, O, S, Se, N(R₃₅), C(R₃₅)(R₃₆), or Si(R₃₅)(R₃₆) (for example, a single bond),

X₃₇ may be N, B, P, C(R₃₇), or Si(R₃₇),

R₃₁ to R₃₈ may each independently be defined as R₃,

a36 may be an integer from 0 to 6,

a35 may be an integer from 0 to 5,

a34 may be an integer from 0 to 4,

a33 may be an integer from 0 to 3,

a32 may be an integer from 0 to 2,

*″ indicates a binding site to T₁ in Formula 1,

* indicates a binding site to M in Formula 1, and

*′ indicates a binding site to T₂ in Formula 1.

In an embodiment, a moiety represented by

in Formula 1 may be selected from groups represented by Formulae A4-1(1) to A4-1(21) and A4-3(1) to A4-3(61):

In Formulae A4-1 (1) to A4-1(21) and A4-3(1) to A4-3(61),

X₄ and R₄ may each independently be the same as described herein,

X₄₁ may be O, S, Se, N(R₄₁), C(R₄₁)(R₄₂), or Si(R₄₁)(R₄₂),

X₄₃ may be N or C(R₄₃),

X₄₄ may be N or C(R₄₄),

X₄₅ may be a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆) (for example, a single bond),

X₄₇ may be N, B, P, C(R₄₇), or Si(R₄₇),

R₄₁ to R₄₈, R_(4a) and R_(4b) may each independently be defined as R₄,

a46 may be an integer from 0 to 6,

a45 may be an integer from 0 to 5,

a44 may be an integer from 0 to 4,

a43 may be an integer from 0 to 3,

a42 may be an integer from 0 to 2,

*′ indicates a binding site to T₂ in Formula 1,

* indicates a binding site to M in Formula 1, and

*″ indicates a binding site to ring CY₁₁ in Formula 1.

In one or more embodiments, in Formula 1,

a moiety represented by

may be selected from groups represented by Formulae CY1-1 to CY1-4, and/or

a moiety represented by

may be selected from groups represented by Formulae CY2-1 to CY2-23, and/or

a moiety represented by

may be selected from groups represented by Formulae CY3-1 to CY3-23, and/or

a moiety represented by

may be selected from groups represented by Formulae CY4-1 to CY4-26, but embodiments of the present disclosure are not limited thereto:

In Formulae CY1-1 to CY1-4, CY2-1 to CY2-23, CY3-1 to CY3-23, and CY4-1 to CY4-26,

X₁ to X₄, X₁₅, and R₁ to R₄ may each independently be the same as described herein,

X₄₅ may be a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆),

X₄₇ may be N, B, P, C(R₄₇), or Si(R₄₇),

R_(1a) and R_(1b) may each independently be defined as R₁,

R_(2a) to R_(2c) may each independently be defined as R₂,

R_(3a) to R_(3c) may each independently be defined as R₃,

R_(4a) to R_(4c), and R₄₅ to R₄₇ may each independently be defined as R₄,

in Formulae CY1-1 to CY1-4, *″ indicates a binding site to ring CY₄ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to ring CY₂ in Formula 1,

in Formulae CY2-1 to CY2-23, *′ indicates a binding site to ring CY₁₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to T₁ in Formula 1,

in Formulae CY3-1 to CY3-23, *″ indicates a binding site to T₁ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to T₂ in Formula 1, and

in Formulae CY4-1 to CY4-26, *′ indicates a binding site to T₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY₁₁ in Formula 1.

In an embodiment,

i) T₁ may be a single bond and R₂ and R₃ may be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a);

ii) T₂ may be *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′ and R₄ and R₅ may be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a);

iii) T₂ may be *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′ and R₃ and R₅ may be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a); or

iv) T₂ may be *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′, R₄ and R₅ may be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, R₃ and R₅ may be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group may be each unsubstituted or substituted with at least one R_(1a).

In an embodiment, the organometallic compound may be represented by one of Formulae 1-1 to 1-4:

In Formulae 1-1 to 1-4,

M, X₁ to X₄, ring CY₁₁, ring CY₁₂, ring CY₂ to ring CY₄, T₁, T₂, X₁₅, R₁ to R₄ and a1 to a4 may each independently be the same as described herein,

ring CY₈ may be defined the same as ring CY₄ described herein,

A₁ to A₄ and B₁ to B₇ may each independently be C or N,

X₄₅ may be a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆),

X₄₇ may be N, B, P, C(R₄₇), or Si(R₄₇),

X₄₉ may be a single bond, O, S, Se, N(R₄₈), C(R₄₈)(R₄₉), or Si(R₄₈)(R₄₉),

T₃ may be selected from a single bond, a double bond, *—N(R₇)—*′, *—B(R₇)—*′, *—P(R₇)—*′, *—C(R₇)(R₈)—*′, *—Si(R₇)(R₈)—*′, *—Ge(R₇)(R₈)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₇)═*′, *═C(R₈)—*′, *—C(R₇)═C(R₈)—*′, *—C(═S)—*′, and *—C≡C—*′, and * and *′ each indicate a binding site to a neighboring atom,

n may be an integer from 1 to 5, wherein, when n is two or more, two or more groups T₃ may be identical to or different from each other,

R₄₅ to R₄₉ may each independently be defined as R₄, and

R₇ and R₈ may each independently be defined as R₅.

In Formula 1, i) two or more groups selected from a plurality of neighboring groups R₁ may optionally be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, ii) two or more groups selected from a plurality of neighboring groups R₂ may optionally be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, iii) two or more groups selected from a plurality of neighboring groups R₃ may optionally be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, iv) two or more groups selected from a plurality of neighboring groups R₄ may optionally be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, and v) two or more groups selected from R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₅, and R₁₆ may optionally be linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a) and R_(1a) is defined the same as above R₁.

For example, each of i) two or more groups selected from a plurality of neighboring groups R₁, ii) two or more groups selected from a plurality of neighboring groups R₂, iii) two or more groups selected from a plurality of neighboring groups R₃, iv) two or more groups selected from a plurality of neighboring groups R₄, and v) two or more groups selected from R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆, may optionally be linked to form a cyclopentadiene group, a cyclohexane group, a cycloheptane group, an adamantane group, a bicycle-heptane group, a bicycle-octane group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a naphthalene group, an anthracene group, a tetracene group, a phenanthrene group, a dihydronaphthalene group, a phenalene group, a benzothiophene group, a benzofuran group, an indene group, an indole group, a benzosilole group, an azabenzothiophene group, an azabenzofuran group, an azaindene group, an azaindole group, and an azabenzosilole group, each unsubstituted or substituted with at least one R_(10a) and R_(1a) is defined the same as above R₁, but embodiments of the present disclosure are not limited thereto.

In the present disclosure, “an azabenzothiophene, an azabenzofuran, an azaindene, an azaindole, an azabenzosilole, an azadibenzothiophene, an azadibenzofuran, an azafluorene, an azacarbazole, and an azadibenzosilole” as used herein each refer to a hetero ring having the same backbone as “a benzothiophene, a benzofuran, an indene, an indole, benzosilole, a dibenzothiophene, a dibenzofuran, a fluorene, a carbazole, and a dibenzosilole”, in which at least one carbon constituting rings thereof is substituted with nitrogen.

In an embodiment, the organometallic compound may be one of Compounds 1 to 160, but embodiments of the present disclosure are not limited thereto:

Formula 1 includes a moiety represented by

X₁ is N, a bond between X₁ and M in Formula 1 is a covalent bond, *′ indicates a binding site to ring CY₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY₄ in Formula 1. Therefore, since the full width at half maximum (FWHM) of the peak of the photoluminescence (PL) spectrum of the organometallic compound represented by Formula 1 and/or the electroluminescence (EL) spectrum of the organic light-emitting device including the organometallic compound may be improved (for example, reduced), the electronic device, for example, the organic light-emitting device, which includes the organometallic compound, may have excellent color purity, high luminescence efficiency, and/or a long lifespan. In an embodiment, the organometallic compound represented by Formula 1 may emit red light and/or near-infrared light having excellent color purity.

In addition, in Formula 1, ring CY₁₂ is connected to ring CY₂ via a single bond, ring CY₂ is connected to ring CY₃ via T₁, ring CY₃ is connected to ring CY₄ via T₂, and ring CY₄ is connected to ring CY₁₁ via a single bond. That is, the organometallic compound represented by Formula 1 may have four cyclometalated rings and have a stereoscopically stable molecular structure. Therefore, an electronic device, for example, an organic light-emitting device, which includes the organometallic compound, may have a long lifespan.

For example, highest occupied molecular orbital (HOMO), lowest unoccupied molecular orbital (LUMO), and triplet (T₁) energy levels of some of the above compounds were evaluated by a DFT method of Gaussian program (structurally optimized at a level of B3LYP, 6-31G(d,p)), and results thereof are shown in Table 1.

TABLE 1 Compound No. HOMO (eV) LUMO (eV) T₁ energy level (eV) 77 −4.589 −1.775 1.961 85 −4.419 −1.876 1.845 86 −4.604 −2.287 1.622 101 −4.640 −2.168 1.743

From Table 1, it is confirmed that the organometallic compound represented by Formula 1 has such electric characteristics that are suitable for use in an electric device, for example, for use as a dopant for an organic light-emitting device.

Synthesis methods of the organometallic compound represented by Formula 1 may be understood by one of ordinary skill in the art by referring to Synthesis Examples provided below.

The organometallic compound represented by Formula 1 is suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer. Thus, another aspect provides an organic light-emitting device that includes: a first electrode; a second electrode; and an organic layer that is disposed between the first electrode and the second electrode and includes an organic layer including an emission layer and at least one of the organometallic compound represented by Formula 1.

The organic light-emitting device may have, due to the inclusion of an organic layer including the organometallic compound represented by Formula 1, a low driving voltage, high efficiency, high power, high quantum efficiency, a long lifespan, a low roll-off ratio, and excellent color purity.

The organometallic compound represented by Formula 1 may be used between a pair of electrodes of the organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host).

The expression “(an organic layer) includes at least one of organometallic compounds” as used herein may include an embodiment in which “(an organic layer) includes identical organometallic compounds represented by Formula 1” and an embodiment in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1.”

For example, the organic layer may include, as the organometallic compound, only Compound 1. In this embodiment, Compound 1 may be included in an emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2.

In this embodiment, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 all may be included in an emission layer).

The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

In an embodiment, in the organic light-emitting device, the first electrode is an anode, and the second electrode is a cathode, and the organic layer further includes a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode, wherein the hole transport region includes a hole injection layer, a hole transport layer, an electron blocking layer, or any combination thereof, and wherein the electron transport region includes a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

The term “organic layer” as used herein refers to a single layer and/or a plurality of layers between the first electrode and the second electrode of the organic light-emitting device. The “organic layer” may include, in addition to an organic compound, an organometallic complex including metal.

The FIGURE is a schematic view of an organic light-emitting device 10 according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with the FIGURE.

The organic light-emitting device 10 includes a first electrode 11, an organic layer 15, and a second electrode 19, which are sequentially stacked.

A substrate may be additionally disposed under the first electrode 11 or above the second electrode 19. For use as the substrate, any substrate that is used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

The first electrode 11 may be formed by depositing or sputtering a material for forming the first electrode 11 on the substrate. The first electrode 11 may be an anode. The material for forming the first electrode 11 may be selected from materials with a high work function to facilitate hole injection. The first electrode 11 may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode may be, for example, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO₂), and zinc oxide (ZnO). In one or more embodiments, magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as the material for forming the first electrode.

The first electrode 11 may have a single-layered structure or a multi-layered structure including two or more layers. For example, the first electrode 11 may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode 110 is not limited thereto.

The organic layer 15 is disposed on the first electrode 11.

The organic layer 15 may include a hole transport region, an emission layer, and an electron transport region.

The hole transport region may be disposed between the first electrode 11 and the emission layer.

The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode 11.

A hole injection layer may be formed on the first electrode 11 by using one or more suitable methods selected from vacuum deposition, spin coating, casting, or Langmuir-Blodgett (LB) deposition.

When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary according to a compound that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. For example, the deposition conditions may include a deposition temperature of about 100° C. to about 500° C., a vacuum pressure of about 10⁻⁸ torr to about 10⁻³ torr, and a deposition rate of about 0.01 Angstroms per second (A/sec) to about 100 Å/sec. However, the deposition conditions are not limited thereto.

When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, a coating speed may be from about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a temperature at which a heat treatment is performed to remove a solvent after coating may be from about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.

The hole transport region may include at least one selected from m-MTDATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4′,4″-tris(N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzene sulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrene sulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrene sulfonate) (PANI/PSS), a compound represented by Formula 201 below, and a compound represented by Formula 202 below:

Ar₁₀₁ and Ar₁₀₂ in Formula 201 may each independently be selected from:

a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group; and

a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a picenylene group, a perylenylene group, and a pentacenylene group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

In Formula 201, xa and xb may each independently be an integer from 0 to 5, or 0, 1, or 2. For example, xa is 1 and xb is 0, but xa and xb are not limited thereto.

R₁₀₁ to R₁₀₈, R₁₁₁ to R₁₁₉, and R₁₂₁ to R₁₂₄ in Formulae 201 and 202 may each independently be selected from:

hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, a pentyl group, a hexyl group, and so on), or a C₁-C₁₀ alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, and so on);

a C₁-C₁₀ alkyl group or a C₁-C₁₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, and a phosphoric acid group or a salt thereof;

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group; and

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, and a pyrenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, and a C₁-C₁ alkoxy group, but embodiments of the present disclosure are not limited thereto, and

R₁₀₉ in Formula 201 may be selected from:

a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group; and

a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, and a pyridinyl group.

According to an embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:

R₁₀₁, R₁₁₁, R₁₁₂, and R₁₀₉ in Formula 201A may be understood by referring to the description provided herein.

For example, the compound represented by Formula 201, and the compound represented by Formula 202 may include compounds HT1 to HT20 illustrated below, but are not limited thereto.

A thickness of the hole transport region may be in a range of about 100 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å. When the hole transport region includes at least one of a hole injection layer and a hole transport layer, the thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, and for example, about 100 Å to about 1,000 Å, and the thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, and for example, about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.

The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

The charge-generation material may be, for example, a p-dopant. The p-dopant may be one selected from a quinone derivative, a metal oxide, and a cyano group-containing compound, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonedimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonedimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenium oxide; and a cyano group-containing compound, such as Compound HT-D1 below, but are not limited thereto.

The hole transport region may include a buffer layer.

Also, the buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.

Then, an emission layer may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied in forming the hole injection layer although the deposition or coating conditions may vary according to a compound that is used to form the emission layer.

Meanwhile, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be selected from materials for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. For example, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.

The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.

The host may include at least one selected from TPBi, TBADN, ADN (also referred to as “DNA”), CBP, CDBP, TCP, mCP, Compound H50, and Compound H51:

In one or more embodiments, the host may further include a compound represented by Formula 301 below.

Ar₁₁₁ and Ar₁₁₂ in Formula 301 may each independently be selected from:

a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group; and

a phenylene group, a naphthylene group, a phenanthrenylene group, and a pyrenylene group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

Ar₁₁₃ to Ar₁₁₆ in Formula 301 may each independently be selected from:

a C₁-C₁₀ alkyl group, a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group; and

a phenyl group, a naphthyl group, a phenanthrenyl group, and a pyrenyl group, each substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group.

g, h, i, and j in Formula 301 may each independently be an integer from 0 to 4, and may be, for example, 0, 1, or 2.

Ar₁₁₃ to Ar₁₁₆ in Formula 301 may each independently be selected from:

a C₁-C₁₀ alkyl group, the substituted with at least one selected from a phenyl group, a naphthyl group, and an anthracenyl group;

a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl, a phenanthrenyl group, and a fluorenyl group;

a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyrenyl group, a phenanthrenyl group, and a fluorenyl group; and

but embodiments of the present disclosure are not limited thereto.

In one or more embodiments, the host may include a compound represented by Formula 302:

Ar₁₂₂ to Ar₁₂₅ in Formula 302 may each independently be defined as Ar₁₁₃ in Formula 301.

Ar₁₂₆ and Ar₁₂₇ in Formula 302 may each independently be a C₁-C₁₀ alkyl group (for example, a methyl group, an ethyl group, or a propyl group).

k and l in Formula 302 may each independently be an integer from 0 to 4. For example, k and l may be 0, 1, or 2.

When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and a blue emission layer. In one or more embodiments, due to a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight, but embodiments of the present disclosure are not limited thereto.

A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. While not wishing to be bound by theory, it is understood that when the thickness of the emission layer is within the range described above, excellent emission characteristics may be exhibited without substantial increase of driving voltage.

Then, an electron transport region may be disposed on the emission layer electron transport region.

The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

For example, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.

When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, at least one of BCP, Bphen, and BAlq but embodiments of the present disclosure are not limited thereto.

A thickness of the hole blocking layer may be in a range of about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have improved hole blocking ability without a substantial increase in driving voltage.

The electron transport layer may further include at least one selected from BCP, Bphen, Alq₃, BAlq, TAZ, and NTAZ.

In one or more embodiments, the electron transport layer may include at least one of ET1 to ET25, but are not limited thereto:

A thickness of the electron transport layer may be in a range of about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.

The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (lithium 8-hydroxyquinolate, LiQ) or ET-D2.

The electron transport region may include an electron injection layer that promotes flow of electrons from the second electrode 19 thereinto.

The electron injection layer may include at least one selected from LiF, NaCl, CsF, Li₂O, and BaO.

A thickness of the electron injection layer may be in a range of about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron injection layer is within the range described above, the electron injection layer may have satisfactory electron injection characteristics without a substantial increase in driving voltage.

The second electrode 19 is disposed on the organic layer 15. The second electrode 19 may be a cathode. A material for forming the second electrode 19 may be selected from metal, an alloy, an electrically conductive compound, and a combination thereof, which have a relatively low work function. For example, lithium (Li), magnesium (Mg), aluminum (A1), aluminum-lithium (A1-Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be used as a material for forming the second electrode 19. In one or more embodiments, to manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode 19.

Hereinbefore, the organic light-emitting device has been described with reference to the FIGURE, but embodiments of the present disclosure are not limited thereto.

Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

The organometallic compound represented by Formula 1 provides high luminescence efficiency. Accordingly, a diagnostic composition including the organometallic compound may have high diagnostic efficiency.

The diagnostic composition may be used in various applications including a diagnosis kit, a diagnosis reagent, a biosensor, and a biomarker.

The term “C₁-C₆₀ alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and non-limiting examples thereof include a methyl group, an ethyl group, a propyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an iso-amyl group, and a hexyl group. The term “C₁-C₆₀ alkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₆₀ alkyl group.

The term “C₁-C₆₀ alkoxy group” as used herein refers to a monovalent group represented by —OA₁₀₁ (wherein A₁₀₁ is the C₁-C₆₀ alkyl group), and non-limiting examples thereof include a methoxy group, an ethoxy group, and an iso-propyloxy group.

The term “C₂-C₆₀ alkenyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon double bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C₂-C₆₀ alkenylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkenyl group.

The term “C₂-C₆₀ alkynyl group” as used herein refers to a hydrocarbon group formed by including at least one carbon-carbon triple bond in the middle or at the terminus of the C₂-C₆₀ alkyl group, and examples thereof include an ethynyl group, and a propynyl group. The term “C₂-C₆₀ alkynylene group” as used herein refers to a divalent group having the same structure as the C₂-C₆₀ alkynyl group.

The term “C₃-C₁₀ cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C₃-C₁₀ cycloalkylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkyl group.

The term “C₁-C₁₀ heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranyl group, and a tetrahydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkyl group.

The term “C₃-C₁₀ cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity, and non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C₃-C₁₀ cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₃-C₁₀ cycloalkenyl group.

The term “C₁-C₁₀ heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Examples of the C₁-C₁₀ heterocycloalkenyl group are a 2,3-dihydrofuranyl group, and a 2,3-dihydrothiophenyl group. The term “C₁-C₁₀ heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C₁-C₁₀ heterocycloalkenyl group.

The term “C₆-C₆₀ aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C₆-C₆₀ arylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C₆-C₆₀ aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C₆-C₆₀ aryl group and the C₆-C₆₀ arylene group each include two or more rings, the rings may be fused to each other.

The term “C₁-C₆₀ heteroaryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, and 1 to 60 carbon atoms. The term “C₁-C₆₀ heteroarylene group” as used herein refers to a divalent group having a carbocyclic aromatic system that has at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom, and 1 to 60 carbon atoms. Non-limiting examples of the C₁-C₆₀ heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C₁-C₆₀ heteroaryl group and the C₁-C₆₀ heteroarylene group each include two or more rings, the rings may be fused to each other.

The term “C₆-C₆₀ aryloxy group” as used herein indicates —OA₁₀₂ (wherein A₁₀₂ is the C₆-C₆₀ aryl group), and a C₆-C₆₀ arylthio group as used herein indicates —SA₁₀₃ (wherein A₁₀₃ is the C₆-C₆₀ aryl group).

The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and no aromaticity in its entire molecular structure. Examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

The term “C₅-C₃₀ carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, 5 to 30 carbon atoms only. The C₅-C₃₀ carbocyclic group may be a monocyclic group or a polycyclic group.

The term “C₁-C₃₀ heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The C₁-C₃₀ heterocyclic group may be a monocyclic group or a polycyclic group.

At least one substituent of the substituted C₅-C₁₅ carbocyclic group, the substituted C₂-C₁₅ heterocyclic group, the substituted C₅-C₃₀ carbocyclic group, the substituted C₂-C₃₀ heterocyclic group, the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be selected from:

deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group;

a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(═O)(Q₁₈)(Q₁₉);

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group;

a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(═O)(Q₂₈)(Q₂₉); and

—N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(═O)(Q₃₈)(Q₃₉), and

Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ may each independently be selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.

Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Example and Examples. However, the organic light-emitting device is not limited thereto. The wording “B was used instead of A” used in describing Synthesis Examples means that an amount of A used was identical to an amount of B used, in terms of a molar equivalent.

EXAMPLES Synthesis Example 1 (Compound 71)

Synthesis of Intermediate 71P-2

Compounds 71A (3.3 grams (g), 10.3 millimoles (mmol)) and 71B (4.2 g, 11.3 mmol) as starting materials, Pd(PPh₃)₄(0.8 g, 0.7 mmol), K₂CO₃ (4.3 g, 30.8 mmol), 120 milliliters (mL) of tetrahydrofuran (THF), and 40 mL of distilled water were mixed and stirred under reflux for 12 hours. After the temperature was lowered to room temperature, methylenechloride (MC) was added to extract the product. The organic layer extracted therefrom was dried over anhydrous magnesium sulfate (MgSO₄) to remove the solvent and filtered. The residue obtained by concentrating the filtrate under reduced pressure was purified by column chromatography with MC:Hexane to obtain 4.1 g (82%) of Intermediate 71P-2.

Synthesis of Intermediate 71P-1

Intermediate 71P-2 (3.9 g, 8.1 mmol) and K₂PtCl₄ (3.7 g, 8.9 mmol) were mixed with 100 mL of acetic acid, and the mixed solution was stirred under reflux for 18 hours to allow the reaction to proceed. After the temperature was lowered, the resulting solid product was filtered and subjected to column chromatography with MC:hexane to obtain 3.0 g (55%) of Intermediate 71P-1.

Synthesis of Compound 71

Intermediate 71P-1 (3.5 g, 5.2 mmol) was allowed to react at a temperature of 300° C. for 18 hours, and then, the temperature was lowered. The resulting product was dissolved in MC and subjected to column chromatography with MC:hexane to obtain 0.9 g (26%) of Compound 71. The obtained compound was identified by Mass and HPLC analysis.

HRMS (MALDI) calcd for C₃₄H₁₈N₄Pt: m/z 677.1179, Found: 677.1185.

Synthesis Example 2 (Compound 72)

Synthesis of Intermediate 72P-2

Compounds 72A (3.0 g, 7.6 mmol) and 71B (3.1 g, 8.3 mmol) as starting materials, Pd(PPh₃)₄(0.6 g, 0.5 mmol), K₂CO₃ (3.1 g, 22.7 mmol), 90 mL of tetrahydrofuran (THF), and 30 mL of distilled water were mixed and stirred under reflux for 12 hours. After the temperature was lowered to room temperature, methylenechloride (MC) was added to extract the product. The organic layer extracted therefrom was dried over anhydrous magnesium sulfate (MgSO₄) to remove the solvent. The residue obtained by concentrating the filtrate under reduced pressure was purified by column chromatography with MC:Hexane to obtain 3.4 g (77%) of Intermediate 72P-2.

Synthesis of Intermediate 72P-1

Intermediate 72P-2 (3.0 g, 5.3 mmol) and K₂PtCl₄ (2.4 g, 5.8 mmol) were mixed with 70 mL of acetic acid, and the mixed solution was stirred under reflux for 18 hours to allow the reaction to proceed. After the temperature was lowered, the resulting solid product was filtered and subjected to column chromatography with MC:hexane to obtain 1.9 g (48%) of Intermediate 72P-1.

Synthesis of Compound 72

Intermediate 72P-1 (1.9 g, 2.5 mmol) was allowed to react at a temperature of 300° C. for 18 hours, and then, the temperature was lowered. The resulting product was dissolved in MC and subjected to column chromatography with MC:hexane to obtain 0.3 g (16%) of Compound 72. The obtained compound was identified by Mass and HPLC analysis.

HRMS (MALDI) calcd for C₄₀H₂₂N₄Pt: m/z 753.1492, Found: 753.1486.

Example 1

An indium tin oxide (ITO) glass substrate was cut to a size of 50 mm×50 mm×0.5 mm (mm=millimeters), and then, sonicated in acetone iso-propyl alcohol and pure water, each for 15 minutes, and then, washed by exposure to UV ozone for 30 minutes.

Subsequently, on the ITO electrode (anode) on the glass substrate, m-MTDATA was deposited at a deposition speed of 1 Angstrom per second (Å/sec) to form a hole injection layer having a thickness of 600 Angstroms (Å), and α-NPD was deposited on the hole injection layer at a deposition speed of 1 Å/sec to form a hole transport layer having a thickness of 250 Å.

Compound 71 (dopant) and CBP (host) were co-deposited on the hole transport layer at a deposition speed of 0.1 Å/sec and a deposition speed of 1 Å/sec, respectively, to form an emission layer having a thickness of 400 Å.

BAlq was deposited on the emission layer at a deposition speed of 1 Å/sec to form a hole blocking layer having a thickness of 50 Å, and Alq₃ was deposited on the hole blocking layer to form an electron transport layer having a thickness of 300 Å, and then, LiF was deposited on the electron transport layer to form an electron injection layer having a thickness of 10 Å, and then, A1 was vacuum deposited on the electron injection layer to form a second electrode (cathode) having a thickness of 1,200 Å, thereby completing the manufacture of an organic light-emitting device having a structure of ITO/m-MTDATA (600 Å)/α-NPD (250 Å)/CBP+10% (Compound 71) (400 Å)/Balq(50 Å)/Alq₃(300 Å)/LiF(10 Å)/Al(1,200 Å).

Example 2 and Comparative Examples A and B

Organic light-emitting devices were manufactured in the same manner as in Example 1, except that in forming an emission layer, for use as a dopant, corresponding compounds shown in Table 2 were used instead of Compound 71.

Evaluation Example 1: Evaluation of Characteristics of Organic Light-Emitting Devices

The driving voltage, external quantum efficiency (EQE), a full width at half maximum (FWHM) and lifespan (T₉₇) of the organic light-emitting devices manufactured according to Examples 1 and 2 and Comparative Examples A and B were evaluated, and results thereof are shown in Table 2. A current-voltage meter (Keithley 2400) and a luminance meter (Minolta Cs-1000A) were used as the evaluation device, and the lifespan (T₉₇) indicates an amount of time that lapsed when luminance was 97% of initial luminance (100%). The lifespan (T₉₇) was indicated by relative values of the lifespan (T₉₇) of the organic light-emitting device of Comparative Example A.

TABLE 2 T₉₇ EQE FWHM (%) Dopant (%) (nm) (at 6000 nit) Example 1 Compound 71 21.9 38.2 374 Example 2 Compound 72 23.8 40.6 623 Comparative Example A Compound A 12.1 56.2 100 Comparative Example B Compound B 10.8 116.5  167

Referring to Table 2, it is confirmed that the organic light-emitting devices of Examples 1 and 2 have improved EQE, FWHM and lifespan characteristics, compared with Comparative Examples A and B.

Since the organometallic compound has excellent electrical characteristics and thermal stability, an organic light-emitting device including the organometallic compound may have excellent FWHM, EQE, and lifespan characteristics. In addition, since the organometallic compound has excellent phosphorescence characteristics, the organometallic compound may be used to provide a diagnostic composition having high diagnostic efficiency.

It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

While one or more embodiments have been described with reference to the FIGURES, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present description as defined by the following claims. 

What is claimed is:
 1. An organometallic compound represented by Formula 1:

wherein, in Formula 1, M is beryllium (Be), magnesium (Mg), aluminum (Al), calcium (Ca), titanium (Ti), manganese (Mn), cobalt (Co), copper (Cu), zinc (Zn), gallium (Ga), germanium (Ge), zirconium (Zr), ruthenium (Ru), rhodium (Rh), palladium (Pd), silver (Ag), rhenium (Re), platinum (Pt), or gold (Au), X₁ is N, X₂ to X₄ are each independently N or C, a bond between X₁ and M is a covalent bond, two bonds selected from a bond between X₂ and M, a bond between X₃ and M, and a bond between X₄ and M are each a coordinate bond and the remaining bond is a covalent bond, ring CY₁₁ and ring CY₁₂ are each independently a C₅-C₁₅ carbocyclic group or a C₁-C₁₅ heterocyclic group, ring CY₂ to ring CY₄ are each independently a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, T₁ and T₂ are each independently selected from a single bond, a double bond, *—N(R₅)—*′, *—B(R₅)—*′, *—P(R₅)—*′, *—C(R₅)(R₆)—*′, *—Si(R₅)(R₆)—*′, *—Ge(R₅)(R₆)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₅)═*′, *═C(R₅)—*′, *—C(R₅)═C(R₆)—*′, *—C(R_(5a))(R_(5b))—C(R_(6a))(R_(6b))—*′, *—C(═S)—*′, and *—C≡C—*′, and * and *′ each indicate a binding site to a neighboring atom, X₁₅ is a single bond, O, S, Se, N(R₁₅), C(R₁₅)(R₁₆), or Si(R₁₅)(R₁₆), R₅ and R₆, and R₁₅ and R₁₆ are optionally linked via a single bond, a double bond, or a first linking group to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, —SF₅, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C₁-C₆₀ alkyl group, a substituted or unsubstituted C₂-C₆₀ alkenyl group, a substituted or unsubstituted C₂-C₆₀ alkynyl group, a substituted or unsubstituted C₁-C₆₀ alkoxy group, a substituted or unsubstituted C₃-C₁₀ cycloalkyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkyl group, a substituted or unsubstituted C₃-C₁₀ cycloalkenyl group, a substituted or unsubstituted C₁-C₁₀ heterocycloalkenyl group, a substituted or unsubstituted C₆-C₆₀ aryl group, a substituted or unsubstituted C₆-C₆₀ aryloxy group, a substituted or unsubstituted C₆-C₆₀ arylthio group, a substituted or unsubstituted C₁-C₆₀ heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉), a1 to a4 are each independently an integer from 0 to 20, two or more groups selected from a plurality of neighboring groups R₁ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), two or more groups selected from a plurality of neighboring groups R₂ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), two or more groups selected from a plurality of neighboring groups R₃ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), two or more groups selected from a plurality of neighboring groups R₄ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), two or more groups selected from R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ are optionally linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a), R_(1a) is defined the same as above R₁, at least one substituent of the substituted C₁-C₆₀ alkyl group, the substituted C₂-C₆₀ alkenyl group, the substituted C₂-C₆₀ alkynyl group, the substituted C₁-C₆₀ alkoxy group, the substituted C₃-C₁₀ cycloalkyl group, the substituted C₁-C₁₀ heterocycloalkyl group, the substituted C₃-C₁₀ cycloalkenyl group, the substituted C₁-C₁₀ heterocycloalkenyl group, the substituted C₆-C₆₀ aryl group, the substituted C₆-C₆₀ aryloxy group, the substituted C₆-C₆₀ arylthio group, the substituted C₁-C₆₀ heteroaryl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is selected from: deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group; a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, and a C₁-C₆₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₃-C₁₀ group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₁₁)(Q₁₂), —Si(Q₁₃)(Q₁₄)(Q₁₅), —B(Q₁₆)(Q₁₇), and —P(═O)(Q₁₈)(Q₁₉); a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group; a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀ heteroaryl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q₂₁)(Q₂₂), —Si(Q₂₃)(Q₂₄)(Q₂₅), —B(Q₂₆)(Q₂₇), and —P(═O)(Q₂₈)(Q₂₉); and —N(Q₃₁)(Q₃₂), —Si(Q₃₃)(Q₃₄)(Q₃₅), —B(Q₃₆)(Q₃₇), and —P(═O)(Q₃₈)(Q₃₉), and Q₁ to Q₉, Q₁₁ to Q₁₉, Q₂₁ to Q₂₉, and Q₃₁ to Q₃₉ are each independently selected from hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₆₀ alkyl group, a C₁-C₆₀) alkyl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₂-C₆₀ alkenyl group, a C₂-C₆₀ alkynyl group, a C₁-C₆₀ alkoxy group, a C₃-C₁₀ cycloalkyl group, a C₁-C₁₀ heterocycloalkyl group, a C₃-C₁₀ cycloalkenyl group, a C₁-C₁₀ heterocycloalkenyl group, a C₆-C₆₀ aryl group, a C₆-C₆₀ aryl group substituted with at least one selected from deuterium, a C₁-C₆₀ alkyl group, and a C₆-C₆₀ aryl group, a C₆-C₆₀ aryloxy group, a C₆-C₆₀ arylthio group, a C₁-C₆₀) heteroaryl group, a monovalent non-aromatic condensed polycyclic group, and a monovalent non-aromatic condensed heteropolycyclic group.
 2. The organometallic compound of claim 1, wherein i) X₂ and X₃ are each N, and X₄ is C; ii) X₂ and X₄ are each N, and X₃ is C; iii) a bond between X₂ and M and a bond between X₃ and M are each a coordinate bond, and a bond between X₄ and M is a covalent bond, or iv) a bond between X₂ and M and a bond between X₄ and M are each a coordinate bond, and a bond between X₃ and M is a covalent bond.
 3. The organometallic compound of claim 1, wherein ring CY₁₁, ring CY₁₂, and ring CY₂ to ring CY₄ are each independently selected from a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a cyclopentadiene group, a 1,2,3,4-tetrahydronaphthalene group, a thiophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrrole group, a pyrazole group, an imidazole group, a triazole group, an oxazole group, an isoxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzooxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, a 5,6,7,8-tetrahydroquinoline group, an indazole group, a benzofluorene group, a benzocarbazole group, a naphthobenzofuran group, a naphthobenzothiophene group, and a naphtobenzosilole group.
 4. The organometallic compound of claim 1, wherein, T₁, and X₁₅ are each a single bond.
 5. The organometallic compound of claim 1, wherein R₁ to R₆, R_(5a), R_(5b), R_(6a), R_(6b), R₁₅, and R₁₆ are each independently selected from: hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, —SF₅, a C₁-C₂₀ alkyl group, and a C₁-C₂₀ alkoxy group; a C₁-C₂₀ alkyl group and a C₁-C₂₀ alkoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₁₀ alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a pyridinyl group, and a pyrimidinyl group; a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, a phenoxy group, and a naphthoxy group; a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, a phenoxy group, and a naphthoxy group, each substituted with at least one selected from deuterium, —F, —Cl, —Br, —I, —CD₃, —CD₂H, —CDH₂, —CF₃, —CF₂H, —CFH₂, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C₁-C₂₀ alkyl group, a C₁-C₂₀ alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cycloctyl group, an adamantanyl group, a norbornanyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a phenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a dibenzosilolyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, and —Si(Q₃₃)(Q₃₄)(Q₃₅); and —N(Q₁)(Q₂), —Si(Q₃)(Q₄)(Q₅), —B(Q₆)(Q₇), and —P(═O)(Q₈)(Q₉), and Q₁ to Q₉ and Q₃₃ to Q₃₅ are each independently selected from: —CH₃, —CD₃, —CD₂H, —CDH₂, —CH₂CH₃, —CH₂CD₃, —CH₂CD₂H, —CH₂CDH₂, —CHDCH₃, —CHDCD₂H, —CHDCDH₂, —CHDCD₃, —CD₂CD₃, —CD₂CD₂H, and —CD₂CDH₂; an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group; and an n-propyl group, an iso-propyl group, an n-butyl group, an iso-butyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an iso-pentyl group, a sec-pentyl group, a tert-pentyl group, a phenyl group, and a naphthyl group, each substituted with at least one selected from deuterium, a C₁-C₁₀ alkyl group, and a phenyl group.
 6. The organometallic compound of claim 1, wherein, in Formula 1, ring CY₂ is a group represented by Formula A2-1′ or A2-2′, ring CY₃ is a group represented by Formula A3-1′, A3-2′, or A3-3′, ring CY₄ is a group represented by Formula A4-1′ or A4-3′, and at least one of Condition 1 to Condition 3 is satisfied: Condition 1 ring CY₂ is a group represented by Formula A2-2′; Condition 2 ring CY₃ is a group represented by Formula A3-2′ or A3-3′; and Condition 3 ring CY₄ is a group represented by Formula A4-3′:

wherein, in Formulae A2-1′, A2-2′, A3-1′, A3-2′, A3-3′, A4-1′, and A4-3′, X₂ to X₄ and ring CY₂ to ring CY₄ are each independently the same as described in claim 1, Y₃, to Y₈ are each independently N, B, P, C, or Si, in Formulae A2-1′ and A2-2′, i) a bond between X₂ and Y₃, a bond between X₂ and Y₄ and a bond between Y₃ and Y₄ are each independently a single bond or a double bond; or ii) Y₃, X₂, and Y₄ form a carbene group, *′ indicates a binding site to ring CY₁₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to T₁ in Formula 1, in Formulae A3-1′, A3-2′, and A3-3′, i) a bond between X₃ and Y₅, a bond between X₃ and Y₆ and a bond between Y₅ and Y₆ are each independently a single bond or a double bond; or ii) Y₅, X₃, and Y₆ form a carbene group, *″ indicates a binding site to T₁ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to T₂ in Formula 1, and in Formulae A4-1′ and A4-3′, i) a bond between X₄ and Y₇, a bond between X₄ and Y₈ and a bond between Y₇ and Y₈ are each independently a single bond or a double bond; or ii) Y₇, X₄, and Y₈ form a carbene group, *′ indicates a binding site to T₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY₁₁ in Formula
 1. 7. The organometallic compound of claim 6, wherein i) ring CY₂ is a group represented by Formula A2-1′, T₁ is a single bond, ring CY₃ is a group represented by Formula A3-1′, T₂ is not a single bond, and ring CY₄ is a group represented by Formula A4-1′; or ii) ring CY₂ is a group represented by Formula A2-1′, Ti is a single bond, ring CY₃ is a group represented by Formula A3-1′, T₂ is a single bond, and ring CY₄ is a group represented by Formula A4-3′.
 8. The organometallic compound of claim 6, wherein the group represented by Formula A2-2′ is a group represented by Formula A2-2, the group represented by Formula A3-2′ is a group represented by Formula A3-2, the group represented by Formula A3-3′ is a group represented by Formula A3-3, and the group represented by Formula A4-3′ is a group represented by Formula A4-3:

wherein, in Formula A2-2, ring CY₂₁ and ring CY₂₂ are each independently defined the same as ring CY₁₁ in claim 1, X₂₅ is a single bond, O, S, Se, N(R₂₅), C(R₂₅)(R₂₆), or Si(R₂₅)(R₂₆), X₂₇ is N, B, P, C(R₂₇), or Si(R₂₇), X₂, *′, *, and *″ are each independently defined the same as X₂, *′, *, and *″ in Formula A2-2′, respectively, and R₂₅ to R₂₇ are each independently defined the same as R₂ in claim 1, in Formulae A3-2 and A3-3, ring CY₃₁ and ring CY₃₂ are each independently defined the same as ring CY₁₁ in claim 1, X₃₅ is a single bond, O, S, Se, N(R₃₅), C(R₃₅)(R₃₆), or Si(R₃₅)(R₃₆), X₃₇ is N, B, P, C(R₃₇), or Si(R₃₇), X₃, *″, *, and *′ are each independently defined the same as X₃, *″, *, and *′ in Formula A3-2′, respectively, and R₃₅ to R₃₇ are each independently defined the same as R₃ in claim 1, and in Formula A4-3, ring CY₄₁ and ring CY₄₂ are each independently defined the same as ring CY₁₁ in claim 1, X₄₅ is a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆), X₄₇ is N, B, P, C(R₄₇), or Si(R₄₇), X₄, *′, *, and *″ are each independently defined the same as X₄, *′, *, and *″ in Formula A4-3′, respectively, and R₄₅ to R₄₇ are each independently defined the same as R₄ in claim
 1. 9. The organometallic compound of claim 1, wherein a moiety represented by

in Formula 1 is selected from groups represented by Formulae A1-1(1) to A1-1(11):

wherein, in Formulae A1-1(1) to A1-1(11), X₁, X₁₅, and R₁ are each independently the same as described in claim 1, R_(1a) and R_(1b) are each independently defined the same as R₁ in claim 1, a18 is an integer from 0 to 8, a16 is an integer from 0 to 6, a15 is an integer from 0 to 5, a14 is an integer from 0 to 4, *″ indicates a binding site to ring CY₄ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to ring CY₂ in Formula
 1. 10. The organometallic compound of claim 1, wherein a moiety represented by

in Formula 1 is selected from groups represented by Formulae A2-1(1) to A2-1(21) and A2-2(1) to A2-2(58):

wherein, in Formulae A2-1(1) to A2-1(21) and A2-2(1) to A2-2(58), X₂ and R₂ are each independently the same as described in claim 1, X₂₁ is O, S, Se, N(R₂₁), C(R₂₁)(R₂₂), or Si(R₂₁)(R₂₂), X₂₃ is N or C(R₂₃), X₂₄ is N or C(R₂₄), X₂₅ is a single bond, O, S, Se, N(R₂₅), C(R₂₅)(R₂₆), or Si(R₂₅)(R₂₆), X₂₇ is N, B, P, C(R₂₇), or Si(R₂₇), R₂₁ to R₂₈ are each independently define the same R₂ in claim 1, a26 is an integer from 0 to 6, a25 is an integer from 0 to 5, a24 is an integer from 0 to 4, a23 is an integer from 0 to 3, a22 is an integer from 0 to 2, *′ indicates a binding site to ring CY₁₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to T₁ in Formula
 1. 11. The organometallic compound of claim 1, wherein a moiety represented by

in Formula 1 is selected from groups represented by Formulae A3-1(1) to A3-1(21), A3-2(1) to A3-2(58), and A3-3(1) to A3-3(58):

wherein, in Formulae A3-1(1) to A3-1(21), A3-2(1) to A3-2(58), and A3-3(1) to A3-3(58), X₃ and R₃ are each independently the same as described in claim 1, X₃₁ is O, S, Se, N(R₃₁), C(R₃₁)(R₃₂), or Si(R₃₁)(R₃₂), X₃₃ is N or C(R₃₃), X₃₄ is N or C(R₃₄), X₃₅ is a single bond, O, S, Se, N(R₃₅), C(R₃₅)(R₃₆), or Si(R₃₅)(R₃₆), X₃₇ is N, B, P, C(R₃₇), or Si(R₃₇), R₃₁ to R₃₈ are each independently defined the same as R₃ in claim 1, a36 is an integer from 0 to 6, a35 is an integer from 0 to 5, a34 is an integer from 0 to 4, a33 is an integer from 0 to 3, a32 is an integer from 0 to 2, *″ indicates a binding site to T₁ in Formula 1, * indicates a binding site to M in Formula 1, and *′ indicates a binding site to T₂ in Formula
 1. 12. The organometallic compound of claim 1, wherein a moiety represented by

in Formula 1 is selected from groups represented by Formulae A4-1(1) to A4-1(21) and A4-3(1) to A4-3(61):

wherein, in Formula A4-1(1) to A4-1(21) and A4-3(1) to A4-3(61), X₄ and R₄ are each independently the same as described in claim 1, X₄₁ is O, S, Se, N(R₄₁), C(R₄₁)(R₄₂), or Si(R₄₁)(R₄₂), X₄₃ is N or C(R₄₃), X₄₄ is N or C(R₄₄), X₄₅ is a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆), X₄₇ is N, B, P, C(R₄₇), or Si(R₄₇), R₄₁ to R₄₈, R_(4a) and R_(4b) are each independently defined the same as R₄ in claim 1, a46 is an integer from 0 to 6, a45 is an integer from 0 to 5, a44 is an integer from 0 to 4, a43 is an integer from 0 to 3, a42 is an integer from 0 to 2, *′ indicates a binding site to T₂ in Formula 1, * indicates a binding site to M in Formula 1, and *″ indicates a binding site to ring CY₁₁ in Formula
 1. 13. The organometallic compound of claim 1, wherein i) T₁ is a single bond and R₂ and R₃ are linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a); ii) T₂ is *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′ and R₄ and R₅ are linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a); iii) T₂ is *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′ and R₃ and R₅ are linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a); or iv) T₂ is *—N(R₅)—*′, *—B(R₅)—*′ or *—P(R₅)—*′, R₄ and R₅ are linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, R₃ and R₅ are linked to form a C₅-C₃₀ carbocyclic group or a C₁-C₃₀ heterocyclic group, wherein the C₅-C₃₀ carbocyclic group and the C₁-C₃₀ heterocyclic group are each unsubstituted or substituted with at least one R_(1a).
 14. The organometallic compound of claim 1, wherein the organometallic compound is represented by one of Formulae 1-1 to 1-4:

wherein, in Formulae 1-1 to 1-4, M, X₁ to X₄, ring CY₁₁, ring CY₁₂, ring CY₂ to ring CY₄, T₁, T₂, X₁₅, R₁ to R₄ and a1 to a4 are each independently the same as described in claim 1, ring CY₈ is defined the same as ring CY₄ in claim 1, A₁ to A₄ and B₁ to B₇ are each independently C or N, X₄₅ is a single bond, O, S, Se, N(R₄₅), C(R₄₅)(R₄₆), or Si(R₄₅)(R₄₆), X₄₇ is N, B, P, C(R₄₇), or Si(R₄₇), X₄₉ is a single bond, O, S, Se, N(R₄₈), C(R₄₈)(R₄₉), or Si(R₄₈)(R₄₉), T₃ is selected from a single bond, a double bond, *—N(R₇)—*′, *—B(R₇)—*′, *—P(R₇)—*′, *—C(R₇)(R₈)—*′, *—Si(R₇)(R₈)—*′, *—Ge(R₇)(R₈)—*′, *—S—*′, *—Se—*′, *—O—*′, *—C(═O)—*′, *—S(═O)—*′, *—S(═O)₂—*′, *—C(R₇)═*′, *═C(R₈)—*′, *—C(R₇)═C(R₈)—*′, *—C(═S)—*′, and *—C≡C—*′, and * and *′ each indicate a binding site to a neighboring atom, n is an integer from 1 to 5, wherein, when n is two or more, two or more groups T₃ are identical to or different from each other, R₄₅ to R₄₉ are each independently defined the same as R₄ in claim 1, and R₇ and R₈ are each independently defined the same as R₅ in claim
 1. 15. The organometallic compound of claim 1, wherein the organometallic compound is one of Compounds 1 to 160:


16. An organic light-emitting device comprising: a first electrode; a second electrode; and an organic layer disposed between the first electrode and the second electrode and comprising an emission layer, wherein the organic layer comprises at least one organometallic compound of claim
 1. 17. The organic light-emitting device of claim 16, wherein the first electrode is an anode, the second electrode is a cathode, the organic layer further comprises a hole transport region between the first electrode and the emission layer and an electronic transport region between the emission layer and the second electrode, the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer or any combination thereof, and the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.
 18. The organic light-emitting device of claim 16, wherein the emission layer comprises the organometallic compound.
 19. The organic light-emitting device of claim 18, wherein the emission layer further comprises a host, and an amount of the host is larger than an amount of the organometallic compound.
 20. A diagnostic composition comprising at least one of the organometallic compound of claim
 1. 